and 4 mo (78.3% vs 63.7%, p[0.04) post-op. P2 cases showed a trend toward improved UC vs controls at 3 mo (74.6% vs 60.4%, p[0.06) CONCLUSIONS: CPTA use appears to accelerate time to UC in age-and performance status-matched men undergoing RARP. We believe that our current findings justify a randomized controlled trial to more accurately gauge whether CPTA should become incorporated into RARP to improve postoperative functional outcomes.
INTRODUCTION AND OBJECTIVES: Radical prostatectomy is the preferred initial treatment for localized prostate cancer in 45% of men with localized prostate cancer in the United States. Although the majority experience long term disease control, current literature reports that up to a third of men will develop disease recurrence. Given the profound changes that have occurred in prostatectomy cohorts due to the rise of active surveillance for low risk disease, we aimed to characterize the pattern of late disease recurrence in a largest contemporary cohort.
METHODS: Consecutive patients who underwent radical prostatectomy between 2003 and 2017 for localized prostate cancer were identified from a prospectively recorded, dedicated prostate cancer database. Patients who received neo-adjuvant androgen deprivation therapy were excluded. Patients were categorized into no recurrence; <12 months (early); 12-60 months (intermediate); and >60 months (late). Clinicopathological characteristics were analyzed using Mann-Whitney U test, Student's t-test, or Chi-square tests where appropriate. In order to assess predictors of recurrence at various time-points, multivariable binomial logistic regression models were utilized.
RESULTS: A total of 2312 patients were included with up to 12 years of follow up data. The average patient had clinically localized prostate cancer, an elevated PSA, and had biopsy ISUP grade group 2. At prostatectomy, 88.7% of patients had ISUP grade group !2. A subgroup of 446 patients had undetectable PSA levels at 5 years after prostatectomy; 11.7% of them progressed to experience biochemical recurrence. In this subgroup, late recurrers had significantly highergrade tumors on ISUP and Gleason sum (p [ <0.001 and p [ 0.001, respectively), larger tumor volumes (p [ 0.032), and higher rates of extraprostatic extension (p [ 0.022). Prostatectomy ISUP grade group was demonstrated as being a significant predictor on logistic regression (OR 2.14, 95% CI 1. 43-3.20, p [ <0.001) .
CONCLUSIONS: This study characterizes the pattern of late recurrence in the largest contemporary active surveillance era cohort. We have identified that prostatectomy ISUP grade group is a strong predictive indicator for late recurrence. We also propose that timing of recurrence resides on a continuum of risk and that the potential concept of dormant micrometastatic involvement requires further research and evaluation.
Source of Funding: None

MP54-09 PROSTATECTOMY IN MEN WITH CLINICALLY POSITIVE LYMPH NODES: COMPARING SURVIVAL IN HIGH RISK CN-, PATHOLOGICALY NEGATIVE NODES, AND PATHOLOGICALLY POSITIVE NODAL DISEASE
Stephen Ryan*, Fady Ghali, San Diego, CA; Moritz Hansen, Matthew Hayn, Jesse Sammon, Portland, ME; Reith Sarkar, James Don Murphy, A. Karim Kader, Brent Rose, San Diego, CA INTRODUCTION AND OBJECTIVES: A prostate cancer (PCa) patient with non-metastatic but clinical positive lymph nodes (cNþ) represents a difficult clinical scenario. Advocates for radical prostatectomy (RP) cite the high false positive rate of imaging (pN-) and overall survival (OS) benefit in men with a 2 positive lymph nodes (pNþ). While others consider cNþ an omen of metastatic disease and advocate for systemic treatment without curative intent therapy. We compared OS after RP in cN-(High Risk), cNþ/pN-(Discordant), and cNþ/pNþ (Concordant).
METHODS: The National Cancer Database was queried for all PCa patients from 2004-2013. Inclusion criteria were known age and PSA at diagnosis, biopsy Gleason score, TNM staging (cT1-3B, cN0/1, M0/X), margin, nodal status and primary treatment modality. cNþ was separated into two cohorts: pN-(Discordant) and pNþ (Concordant). RPs for High Risk PCa (cT3a/b or GS 8 or PSA >20) with cN-was used as a comparison. OS was analyzed with Kaplan Meier (KMA) and Cox proportional hazard model combing demographic, clinical, and pathological factors.
RESULTS: 4944 cNþ men were identified (21.7% RP, 27.5% systemic therapy only). Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
